Dataset Information

Assessing Customized Multivalent Chemokine-Binding Peptide Treatment in a Murine Model of Coxsackievirus B3 Infection

ABSTRACT: This study investigates the therapeutic potential of BK1.3, a synthetic Evasin-derived peptide, in a murine model of Coxsackievirus B3 (CVB3)-induced viral myocarditis. Myocarditis, an inflammatory disease of the heart muscle, is often triggered by viral infections and driven by excessive immune cell infiltration, mediated by chemokines. BK1.3 selectively targets and inhibits key CC chemokines involved in inflammation, potentially mitigating immune-mediated cardiac damage while preserving essential host defense mechanisms. Beyond its impact on cardiac inflammation, CVB3 infection induces systemic effects, including metabolic disturbances and liver dysfunction. The liver plays a critical role in regulating energy homeostasis and immune responses during infection, making it essential to understand how CVB3 alters hepatic metabolism and whether BK1.3 treatment influences these changes. To explore the metabolic adaptations of the liver during CVB3 infection and under BK1.3 treatment, we conducted a comprehensive proteomic analysis of liver tissue. Our goal was to assess infection-induced changes in protein expression related to metabolism, as well as to determine the extent to which BK1.3 modulates these processes. To interpret the functional implications of the observed proteomic changes, we applied HepatoKin1, a computational liver metabolism model, integrating protein abundance data to simulate metabolic pathway activity. This approach provided insights into how viral infection reprograms hepatic metabolism and how targeted chemokine inhibition may affect these adapatations. The dataset offers a valuable resource for understanding systemic metabolic responses in murine viral myocarditis and evaluating the potential benefits of chemokine-targeted therapy.

INSTRUMENT(S): timsTOF Pro

ORGANISM(S): Coxsackievirus Mus Musculus (mouse)

TISSUE(S): Liver

SUBMITTER: Anja Freiwald

LAB HEAD: Prof. Dr. med. Antje Beling

PROVIDER: PXD060461 | Pride | 2025-05-07

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

			Action	DRS
	20230827_Mouse-RefProteome_UP000000589_10090.fasta	Fasta
	20240201_PRO1_AN_001_50-0157_BelingCvb3Infection-liver_P00_QC-001.d.Zip	Other
	20240201_PRO1_AN_002_50-0157_BelingCvb3Infection-liver_P01_A05.d.Zip	Other
	20240201_PRO1_AN_003_50-0157_BelingCvb3Infection-liver_P01_E07.d.Zip	Other
	20240201_PRO1_AN_004_50-0157_BelingCvb3Infection-liver_P01_C09.d.Zip	Other

Items per page:

1 - 5 of 82

Publications

Assessing customized multivalent chemokine-binding peptide treatment in a murine model of coxsackievirus B3 myocarditis.

Kelm Nicolas N Kespohl Meike M Smagurauskaite Gintare G Vales Serena S Karuppanan Kalimuthu K Mburu Philomena P Thiele Arne A Pinkert Sandra S Bukur Thomas T Mülleder Michael M Berndt Nikolaus N Klingel Karin K Gaida Matthias M MM Bhattacharya Shoumo S Beling Antje A

Basic research in cardiology 20250226 2

Myocarditis, an inflammatory disease of the heart muscle, is often triggered by viral infections. This inflammation, which can lead to severe cardiac dysfunction and adverse outcomes, is mediated by various CC and CXC chemokines that interact with receptors in a "one-to-many" fashion. Ticks have evolved chemokine-binding salivary proteins known as Evasins, which efficiently suppress inflammation. This study explores a tailored Evasin-derived CC chemokine-targeting strategy using a 17-mer synthet ...[more]

PMID: 40009121

Similar Datasets

Project description:Theiler’s murine encephalomyelitis virus (TMEV) induces different diseases in the central nervous system (CNS) and heart, depending on the mouse strains and time course, where cytokines play a key role for viral clearance and immune-mediated pathology (immunopathology). In SJL/J mice, TMEV infection causes chronic TMEV-induced demyelinating disease (TMEV-IDD) in the spinal cord around 1 month post infection (p.i.). Unlike other immunopathology models, both pro-inflammatory and anti-inflammatory cytokines can play dual roles in TMEV-IDD. Pro-inflammatory cytokines play a beneficial role in viral clearance while they also play a detrimental role in immune-mediated demyelination. Anti-inflammatory cytokines suppress not only protective anti-viral immune responses but also detrimental autoreactive immune responses. On the other hand, in C3H mice, TMEV infection induces a non-CNS disease, myocarditis, with three phases: phase I, viral pathology with interferon and chemokine responses; phase II, immunopathology mediated by acquired immune responses; and phase III, cardiac fibrosis. Although the precise mechanism how a single virus, TMEV, induces the distinct diseases in different organs is unclear, principal component analysis (PCA) of transcriptome data allows us to identify the key factors contributing to distinct immunopathology. The PCA demonstrated that in vitro infection of a cardiomyocyte cell line could reproduce the transcriptome profile of phase I in TMEV-induced myocarditis; distinct interferon/chemokine-related responses were induced in vitro in infected cardiomyocytes, but not in infected neuronal cells. In addition, the PCA of in vivo CNS transcriptome data showed that decreased lymphatic marker expression was associated with inflammation in TMEV infection. Here, dysfunction of lymphatic vessels may contribute to immunopathology by delaying clearance of cytokines and immune cells from the inflammatory site, although this might confine the virus at the site, preventing virus spread via lymphatic vessels. On the other hand, in the heart, dysfunction of lymphatics was associated with reduced lymphatic muscle contractility by pro-inflammatory cytokines. Therefore, TMEV infection could induce different cytokine expressions as well as lymphatic vessel dysfunction by the distinct mechanism between the CNS and heart, which might contribute to organ-specific immunopathology.